tirzepatide and antidepressants A recent post hoc analysis published in Obesity found vs. placebo was not associated with increased risk of depression symptoms. Rates of suicidal ideation behavior were low and similar to Molecular mechanisms underpinning tirzepatide activity

Priority Review Designation: If granted, compresses the review to approximately 6 months, potentially delivering approval as early as Q3 2027 rather than Q1Q2 2028

Together, these changes significantly lower the analogs affinity for IGF-binding proteins the regulatory proteins that normally limit how much circulating IGF-1 reaches cellular receptors

This group has been the focus of the most bone health research over the past 3 decades

Things To Know Mounjaro uses dual hormone technology targeting GIP and GLP-1 receptors simultaneously Trulicity focuses solely on the GLP-1 pathway for blood sugar control Both medications require once-weekly injections administered subcutaneously Mounjaro typically produces greater A1C reductions averaging 2.0% to 2.3% Trulicity has a longer track record with over 10 years of real-world use Weight loss tends to be more significant with Mounjaro due to its dual action Side effects for both primarily involve gastrointestinal symptoms Mounjaro is available in higher maximum doses than Trulicity How Mounjaro and Trulicity Work Differently The fundamental difference in how these medications function explains much of their varying results

Treatment of symptoms once they start is generally used when episodes occur less frequently (i.e., less than once every 2 month) or when preventive therapy has not worked